Balderton Capital is a European venture investor with a portfolio spanning financial technology and internet businesses.
The round was led by Balderton Capital with backing from TQ Ventures, Earlybird, and Seedcamp.
"Tilt has an incredibly exciting journey ahead. We are thrilled to have the backing of the exceptional team at Balderton Capital, along with our existing investors in this round. This support will enable us to scale the Tilt platform, expand the team, and deepen our engagement with our growing community,"
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
The investment round was led by New York-based Coefficient Capital with participation from multiple venture firms.
"The way ZOE combines their own science and data to drive huge shifts in consumer behavior towards health immediately impressed us"
Bessemer Venture Partners led the round to fund international expansion and product development.
"Carwow’s consumer proposition is just as exciting, which is helping make car changing simpler for consumers across Europe – and with over 9 million car changes a year alone in the UK, we’re looking forward to supporting the Management team in growing the business and delivering on its true potential. Carwow’s focus on using its content expertise and footprint to drive its commerce services through dealer partnerships makes it unique and compelling in the category."
The London startup will use the capital to expand its team, develop next-generation products, and demonstrate clinical performance.
"This could be the defining product in personal health monitoring in the coming decade, and an essential tool for patients and clinicians in diagnosing and treating many chronic diseases as well. Renato and Rafael have a compelling user-centric vision to revolutionise chronic disease management and preventative care, and the credibility and knowledge to execute in this vital area."
